Peter Jenner - Publications

Affiliations: 
Pharmacology Kings College London, London, England, United Kingdom 

206 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. European Journal of Pharmacology. 766: 25-30. PMID 26415982 DOI: 10.1016/j.ejphar.2015.09.028  0.44
2015 Jenner P. Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future. Translational Neurodegeneration. 4: 3. PMID 25973178 DOI: 10.1186/2047-9158-4-3  0.56
2015 Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. European Journal of Pharmacology. 747: 160-5. PMID 25499739 DOI: 10.1016/j.ejphar.2014.11.038  0.44
2015 Broom L, Jenner P, Rose S. Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP+ toxicity. Experimental Neurology. 263: 1-7. PMID 25218309 DOI: 10.1016/j.expneurol.2014.09.005  0.44
2015 Brzozowski MJ, Jenner P, Rose S. Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP+-induced neuronal toxicity Journal of Neural Transmission. 122: 779-788. DOI: 10.1007/s00702-014-1334-8  0.56
2014 Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, Allen R. Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Medicine. 15: 1288-301. PMID 25201131 DOI: 10.1016/j.sleep.2014.05.009  0.44
2014 Jenner P. An overview of adenosine A2A receptor antagonists in Parkinson's disease. International Review of Neurobiology. 119: 71-86. PMID 25175961 DOI: 10.1016/B978-0-12-801022-8.00003-9  0.56
2014 Papathanou M, Jenner P, Iravani M, Jackson M, Stockwell K, Strang I, Zeng BY, McCreary AC, Rose S. The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats. European Journal of Pharmacology. 741: 304-10. PMID 25160743 DOI: 10.1016/j.ejphar.2014.08.004  0.44
2014 Jenner P. A late appearance by the dopamine D-3 receptor. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1094-6. PMID 25044342 DOI: 10.1002/mds.25958  0.56
2014 Iravani MM, Sadeghian M, Rose S, Jenner P. Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss. Journal of Neural Transmission (Vienna, Austria : 1996). 121: 1493-505. PMID 24781752 DOI: 10.1007/s00702-014-1223-1  0.44
2014 Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Practical Neurology. 14: 310-22. PMID 24699931 DOI: 10.1136/practneurol-2013-000741  0.44
2014 Uchida S, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T. Adenosine Aâ‚‚A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. Journal of Pharmacological Sciences. 124: 480-5. PMID 24681641 DOI: DN/JST.JSTAGE/jphs/13250FP  0.44
2014 Yamada K, Kobayashi M, Shiozaki S, Ohta T, Mori A, Jenner P, Kanda T. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology. 231: 2839-49. PMID 24488405 DOI: 10.1007/s00213-014-3454-0  0.44
2014 Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P. Proteomic analysis of striatum from MPTP-treated marmosets (Callithrix jacchus) with L-DOPA-induced dyskinesia of differing severity. Journal of Molecular Neuroscience : Mn. 52: 302-12. PMID 24150990 DOI: 10.1007/s12031-013-0145-y  0.44
2014 Jackson MJ, Swart T, Pearce RKB, Jenner P. Cholinergic manipulation of motor disability and l-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets Journal of Neural Transmission. 121: 163-169. PMID 23959162 DOI: 10.1007/s00702-013-1082-1  0.56
2013 Zeng BY, Salvage S, Jenner P. Effect and mechanism of acupuncture on Alzheimer's disease. International Review of Neurobiology. 111: 181-95. PMID 24215923 DOI: 10.1016/B978-0-12-411545-3.00009-2  0.44
2013 Zeng BY, Salvage S, Jenner P. Current development of acupuncture research in Parkinson's disease. International Review of Neurobiology. 111: 141-58. PMID 24215921 DOI: 10.1016/B978-0-12-411545-3.00007-9  0.44
2013 Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T. Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacology, Biochemistry, and Behavior. 114: 23-30. PMID 24201052 DOI: 10.1016/j.pbb.2013.10.022  0.44
2013 Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, Rose S, Jairaj M, Tayarani-Binazir KA, Syme A. Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents. Bioorganic & Medicinal Chemistry Letters. 23: 5279-82. PMID 23973169 DOI: 10.1016/j.bmcl.2013.08.007  0.44
2013 Jenner P, Morris HR, Robbins TW, Goedert M, Hardy J, Ben-Shlomo Y, Bolam P, Burn D, Hindle JV, Brooks D. Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. Journal of Parkinson's Disease. 3: 1-11. PMID 23938306 DOI: 10.3233/JPD-130175  0.56
2013 Jenner P. Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease. Neurologic Clinics. 31: S17-35. PMID 23931952 DOI: 10.1016/j.ncl.2013.04.010  0.56
2013 Kadowaki Horita T, Kobayashi M, Mori A, Jenner P, Kanda T. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology. 230: 345-52. PMID 23748382 DOI: 10.1007/s00213-013-3158-x  0.44
2013 Ailane S, Long P, Jenner P, Rose S. Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra. The European Journal of Neuroscience. 38: 2468-76. PMID 23692556 DOI: 10.1111/ejn.12231  0.44
2013 Jenner P. A cup of coffee a day keeps dyskinesia away? Movement Disorders : Official Journal of the Movement Disorder Society. 28: 265-7. PMID 23447426 DOI: 10.1002/mds.25409  0.56
2013 Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Biology & Medicine. 62: 132-44. PMID 23380027 DOI: 10.1016/j.freeradbiomed.2013.01.018  0.56
2013 Papathanou M, van der Laan R, Jenner P, Rose S, McCreary AC. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1072-9. PMID 23125107 DOI: 10.1002/mds.25218  0.44
2013 Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 24-30. PMID 22927094 DOI: 10.1002/mds.25032  0.44
2012 Iglesias-González J, Sánchez-Iglesias S, Méndez-Álvarez E, Rose S, Hikima A, Jenner P, Soto-Otero R. Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase. Neurochemical Research. 37: 2150-60. PMID 22821477 DOI: 10.1007/s11064-012-0838-6  0.44
2012 Long P, Samnakay P, Jenner P, Rose S. A yeast two-hybrid screen reveals that osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to microtubule stability, apoptosis and protein degradation in the human brain. The European Journal of Neuroscience. 36: 2733-42. PMID 22779921 DOI: 10.1111/j.1460-9568.2012.08189.x  0.44
2012 Bajic N, Jenner P, Ballard CG, Francis PT. Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 1467-76. PMID 22592936 DOI: 10.1007/s00702-012-0816-9  0.56
2012 Iravani MM, Sadeghian M, Leung CC, Jenner P, Rose S. Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor. Neuroscience Letters. 510: 138-42. PMID 22281445 DOI: 10.1016/j.neulet.2012.01.022  0.44
2012 Tayarani-Binazir KA, Jackson MJ, Strang I, Jairaj M, Rose S, Jenner P. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat. Behavioural Pharmacology. 23: 126-33. PMID 22236652 DOI: 10.1097/FBP.0b013e32834f9f82  0.56
2012 Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 19: 1502-8. PMID 22221452 DOI: 10.1111/j.1468-1331.2011.03593.x  0.44
2012 Iravani MM, Mccreary AC, Jenner P. Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia Parkinsonism and Related Disorders. 18: S123-S125. PMID 22166408  0.56
2012 Jenner P. Mitochondria, monoamine oxidase B and Parkinson's disease Basal Ganglia. 2: S3-S7. DOI: 10.1016/j.baga.2012.06.006  0.56
2011 Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2316-23. PMID 21953831 DOI: 10.1002/mds.23926  0.56
2011 Brotchie J, Jenner P. New approaches to therapy. International Review of Neurobiology. 98: 123-50. PMID 21907085 DOI: 10.1016/B978-0-12-381328-2.00005-5  0.56
2011 Iravani MM, Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of Neural Transmission (Vienna, Austria : 1996). 118: 1661-90. PMID 21881839 DOI: 10.1007/s00702-011-0698-2  0.56
2011 Jenner P, McCreary AC, Scheller DKA. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression Journal of Neural Transmission. 118: 1691-1702. PMID 21881838 DOI: 10.1007/s00702-011-0703-9  0.56
2011 Brzozowski MJ, Alcantara SL, Iravani MM, Rose S, Jenner P. The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression. Brain Research. 1404: 21-30. PMID 21737065 DOI: 10.1016/j.brainres.2011.05.063  0.56
2011 Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1049-55. PMID 21626550 DOI: 10.1002/mds.23732  0.44
2011 Papathanou M, Rose S, McCreary A, Jenner P. Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. The European Journal of Neuroscience. 33: 2247-54. PMID 21615558 DOI: 10.1111/j.1460-9568.2011.07704.x  0.56
2011 Hansard MJ, Jackson MJ, Smith LA, Rose S, Jenner P. A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Behavioural Pharmacology. 22: 269-74. PMID 21522056 DOI: 10.1097/FBP.0b013e328345ca37  0.56
2011 Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. British Journal of Pharmacology. 164: 1357-91. PMID 21486284 DOI: 10.1111/j.1476-5381.2011.01426.x  0.44
2011 Jackson MJ, Jenner P. The MPTP-treated primate, with specific reference to the use of the common marmoset (Callithrix jacchus) Neuromethods. 61: 371-400. DOI: 10.1007/978-1-61779-298-4_20  0.44
2010 Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets Experimental Neurology. 226: 320-327. PMID 20843474 DOI: 10.1016/j.expneurol.2010.09.007  0.56
2010 Johnston LC, Jackson MJ, Rose S, McCreary AC, Jenner P. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2059-66. PMID 20721904 DOI: 10.1002/mds.23249  0.56
2010 Zeng BY, Iravani MM, Jackson MJ, Rose S, Parent A, Jenner P. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiology of Disease. 40: 599-607. PMID 20713157 DOI: 10.1016/j.nbd.2010.08.004  0.56
2010 Bukhatwa S, Zeng BY, Rose S, Jenner P. The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain. Brain Research. 1354: 236-42. PMID 20678493 DOI: 10.1016/j.brainres.2010.07.060  0.56
2010 Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, Rose S, Jairaj M, Tayarani-Binazir KA, Syme A. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. European Journal of Medicinal Chemistry. 45: 4035-42. PMID 20646792 DOI: 10.1016/j.ejmech.2010.05.062  0.44
2010 Iczkiewicz J, Broom L, Cooper JD, Wong AM, Rose S, Jenner P. The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. Journal of Neurochemistry. 114: 1792-804. PMID 20626561 DOI: 10.1111/j.1471-4159.2010.06896.x  0.56
2010 Jones CA, Johnston LC, Jackson MJ, Smith LA, van Scharrenburg G, Rose S, Jenner PG, McCreary AC. An in vivo pharmacological evaluation of pardoprunox (SLV308) - A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease European Neuropsychopharmacology. 20: 582-593. PMID 20434890 DOI: 10.1016/j.euroneuro.2010.03.001  0.56
2010 Stocchi F, Jenner P, Obeso JA. When do levodopa motor fluctuations first appear in Parkinson's disease? European Neurology. 63: 257-66. PMID 20332641 DOI: 10.1159/000300647  0.44
2010 Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. European Journal of Pharmacology. 635: 109-16. PMID 20303948 DOI: 10.1016/j.ejphar.2010.03.006  0.56
2010 Bukhatwa S, Zeng BY, Rose S, Jenner P. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Brain Research. 1326: 174-83. PMID 20176003 DOI: 10.1016/j.brainres.2010.02.045  0.56
2010 Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 377-84. PMID 20108359 DOI: 10.1002/mds.22960  0.56
2010 Stockwell KA, Scheller DKA, Smith LA, Rose S, Iravani MM, Jackson MJ, Jenner P. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets Experimental Neurology. 221: 79-85. PMID 19833125 DOI: 10.1016/j.expneurol.2009.10.004  0.56
2010 Jackson MJ, Andree TH, Hansard M, Hoffman DC, Hurtt MR, Kehne JH, Pitler TA, Smith LA, Stack G, Jenner P. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa. Journal of Neural Transmission (Vienna, Austria : 1996). 117: 55-67. PMID 19809864 DOI: 10.1007/s00702-009-0323-9  0.56
2010 Zeng BY, Balfour RH, Jackson MJ, Rose S, Jenner P. Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets. Journal of Neural Transmission (Vienna, Austria : 1996). 117: 45-51. PMID 19771390 DOI: 10.1007/s00702-009-0315-9  0.56
2009 Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism & Related Disorders. 15: S18-23. PMID 20123550 DOI: 10.1016/S1353-8020(09)70829-6  0.56
2009 Jenner P, Könen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clinical Therapeutics. 31: 2698-711. PMID 20110012 DOI: 10.1016/j.clinthera.2009.10.018  0.56
2009 Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, Tolosa E. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 16: 1090-9. PMID 19723294 DOI: 10.1111/j.1468-1331.2009.02793.x  0.44
2009 Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson's disease. Handbook of Experimental Pharmacology. 589-615. PMID 19639294 DOI: 10.1007/978-3-540-89615-9_18  0.56
2009 Stockwell KA, Scheller D, Rose S, Jackson MJ, Tayarani-Binazir K, Iravani MM, Smith LA, Olanow CW, Jenner P. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction Experimental Neurology. 219: 533-542. PMID 19619533 DOI: 10.1016/j.expneurol.2009.07.011  0.56
2009 Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 16: 982-9. PMID 19538218 DOI: 10.1111/j.1468-1331.2009.02697.x  0.44
2009 Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism & Related Disorders. 15: 406-13. PMID 19446490 DOI: 10.1016/j.parkreldis.2008.12.006  0.56
2009 Bukhatwa S, Iravani MM, Zeng BY, Cooper JD, Rose S, Jenner P. An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat. Journal of Neurochemistry. 109: 52-9. PMID 19187437 DOI: 10.1111/j.1471-4159.2009.05956.x  0.56
2008 Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Annals of Neurology. 64: S16-29. PMID 19127585 DOI: 10.1002/ana.21489  0.56
2008 Jenner P. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities. Movement Disorders : Official Journal of the Movement Disorder Society. 23: S585-98. PMID 18781676 DOI: 10.1002/mds.22022  0.56
2008 Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature Reviews. Neuroscience. 9: 665-77. PMID 18714325 DOI: 10.1038/nrn2471  0.56
2008 Jenner P. Dopamine agonists in Parkinson's disease - Focus on non-motor symptoms European Journal of Neurology. 15: 1. PMID 18702735 DOI: 10.1111/j.1468-1331.2008.02211.x  0.44
2008 Iravani MM, Sadeghian M, Leung CC, Tel BC, Rose S, Schapira AH, Jenner P. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Experimental Neurology. 212: 522-31. PMID 18571649 DOI: 10.1016/j.expneurol.2008.04.037  0.44
2008 MacInnes N, Iravani MM, Perry E, Piggott M, Perry R, Jenner P, Ballard C. Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 869-78. PMID 18401540 DOI: 10.1007/s00702-008-0027-6  0.56
2008 Stockwell KA, Virley DJ, Perren M, Iravani MM, Jackson MJ, Rose S, Jenner P. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets Experimental Neurology. 211: 172-179. PMID 18321484 DOI: 10.1016/j.expneurol.2008.01.019  0.56
2008 Lane EL, Cheetham S, Jenner P. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 423-9. PMID 18250952 DOI: 10.1007/s00702-007-0854-x  0.44
2007 Jenner P. Oxidative stress and Parkinson's disease. Handbook of Clinical Neurology. 83: 507-20. PMID 18808931 DOI: 10.1016/S0072-9752(07)83024-7  0.56
2007 Zubair M, Jackson MJ, Tayarani-Binazir K, Stockwell KA, Smith LA, Rose S, Olanow W, Jenner P. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Experimental Neurology. 208: 177-84. PMID 17935716 DOI: 10.1016/j.expneurol.2007.05.002  0.56
2007 Iczkiewicz J, Rose S, Jenner P. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Experimental Neurology. 207: 95-106. PMID 17643430 DOI: 10.1016/j.expneurol.2007.05.030  0.56
2007 Hurley MJ, Patel PH, Jackson MJ, Smith LA, Rose S, Jenner P. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia. The European Journal of Neuroscience. 26: 171-7. PMID 17614947 DOI: 10.1111/j.1460-9568.2007.05638.x  0.44
2007 Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. Journal of Neuropathology and Experimental Neurology. 66: 329-36. PMID 17483689 DOI: 10.1097/nen.0b013e318053716a  0.44
2007 Kuoppamäki M, Al-Barghouthy G, Jackson MJ, Smith LA, Quinn N, Jenner P. L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates Journal of Neural Transmission. 114: 1147-1153. PMID 17446998 DOI: 10.1007/s00702-007-0727-3  0.44
2007 Litvan I, Halliday G, Hallett M, Goetz CG, Rocca W, Duyckaerts C, Ben-Shlomo Y, Dickson DW, Lang AE, Chesselet MF, Langston WJ, Di Monte DA, Gasser T, Hagg T, Hardy J, ... Jenner P, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. Journal of Neuropathology and Experimental Neurology. 66: 251-7. PMID 17413315 DOI: 10.1097/nen.0b013e3180415e42  0.44
2007 Katzenschlager R, Jackson MJ, Rose S, Stockwell K, Tayarani-Binazir KA, Zubair M, Smith LA, Jenner P, Lees AJ. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 715-9. PMID 17373723 DOI: 10.1002/mds.21256  0.44
2007 Rose S, Scheller DK, Breidenbach A, Smith L, Jackson M, Stockwell K, Jenner P. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behavioural Pharmacology. 18: 155-60. PMID 17351422 DOI: 10.1097/FBP.0b013e3280ebb400  0.44
2007 Rose S, Ramsay Croft N, Jenner P. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Research. 1133: 110-4. PMID 17196564 DOI: 10.1016/j.brainres.2006.10.038  0.56
2007 Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Experimental Neurology. 204: 162-70. PMID 17113078 DOI: 10.1016/j.expneurol.2006.10.005  0.56
2006 Carotti A, Altomare C, Catto M, Gnerre C, Summo L, De Marco A, Rose S, Jenner P, Testa B. Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins. Chemistry & Biodiversity. 3: 134-49. PMID 17193252 DOI: 10.1002/cbdv.200690017  0.56
2006 Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery. 5: 845-54. PMID 17016425 DOI: 10.1038/nrd2087  0.44
2006 Iczkiewicz J, Jackson MJ, Smith LA, Rose S, Jenner P. Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Research. 1118: 239-50. PMID 16962083 DOI: 10.1016/j.brainres.2006.08.036  0.56
2006 Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. The Journal of Pharmacology and Experimental Therapeutics. 319: 1225-34. PMID 16959959 DOI: 10.1124/jpet.106.110429  0.44
2006 Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. European Journal of Pharmacology. 546: 82-7. PMID 16925991 DOI: 10.1016/j.ejphar.2006.07.017  0.56
2006 Zeng BY, Bukhatwa S, Hikima A, Rose S, Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Annals of Neurology. 60: 248-52. PMID 16862581 DOI: 10.1002/ana.20932  0.56
2006 Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clinical Neuropharmacology. 29: 112-25. PMID 16772809 DOI: 10.1097/01.WNF.0000220818.71231.DF  0.56
2006 Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology. 66: S24-36. PMID 16717250  0.56
2006 Zeng BY, Iravani MM, Lin ST, Irifune M, Kuoppamäki M, Al-Barghouthy G, Smith L, Jackson MJ, Rose S, Medhurst AD, Jenner P. MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome European Journal of Neuroscience. 23: 1766-1774. PMID 16623833 DOI: 10.1111/j.1460-9568.2006.04718.x  0.56
2006 Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Pramipexole protects against MPTP toxicity in non-human primates. Journal of Neurochemistry. 96: 1315-21. PMID 16464239 DOI: 10.1111/j.1471-4159.2005.03625.x  0.44
2006 Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacology and Therapeutics. 111: 715-728. PMID 16458973 DOI: 10.1016/j.pharmthera.2005.12.001  0.56
2006 Iravani MM, Haddon CO, Rose S, Jenner P. 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor Brain Research. 1067: 256-262. PMID 16388785 DOI: 10.1016/j.brainres.2005.10.086  0.56
2006 Lane EL, Cheetham SC, Jenner P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Experimental Neurology. 197: 284-90. PMID 16005456 DOI: 10.1016/j.expneurol.2005.06.006  0.44
2005 Iravani MM, Costa S, Al-Bargouthy G, Jackson MJ, Zeng BY, Kuoppamäki M, Obeso JA, Jenner P. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia. The European Journal of Neuroscience. 22: 1305-18. PMID 16190886 DOI: 10.1111/j.1460-9568.2005.04308.x  0.56
2005 Abd El Mohsen MM, Iravani MM, Spencer JP, Rose S, Fahim AT, Motawi TM, Ismail NA, Jenner P. Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants. Biochemical and Biophysical Research Communications. 336: 386-91. PMID 16139799 DOI: 10.1016/j.bbrc.2005.07.201  0.56
2005 Hyun DH, Lee M, Halliwell B, Jenner P. Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. Journal of Neuroscience Research. 82: 232-44. PMID 16130151 DOI: 10.1002/jnr.20638  0.56
2005 Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. The European Journal of Neuroscience. 22: 317-30. PMID 16045485 DOI: 10.1111/j.1460-9568.2005.04220.x  0.56
2005 Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology. 65: S3-5. PMID 16030291  0.56
2005 Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets European Journal of Neuroscience. 21: 3240-3250. PMID 16026462 DOI: 10.1111/j.1460-9568.2005.04169.x  0.44
2005 Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opinion On Investigational Drugs. 14: 729-38. PMID 16004599 DOI: 10.1517/13543784.14.6.729  0.56
2005 Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, et al. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination]. Neurología (Barcelona, Spain). 20: 180-8. PMID 15891947  0.44
2005 Zeng BY, Medhurst AD, Jackson M, Rose S, Jenner P. Proteasomal activity in brain differs between species and brain regions and changes with age Mechanisms of Ageing and Development. 126: 760-766. PMID 15888331 DOI: 10.1016/j.mad.2005.01.008  0.56
2005 Iczkiewicz J, Rose S, Jenner P. Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. The European Journal of Neuroscience. 21: 1911-20. PMID 15869484 DOI: 10.1111/j.1460-9568.2005.04009.x  0.56
2005 Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. The European Journal of Neuroscience. 21: 841-54. PMID 15787691 DOI: 10.1111/j.1460-9568.2005.03915.x  0.44
2005 Lane EL, Cheetham SC, Jenner P. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. The European Journal of Neuroscience. 21: 179-86. PMID 15654855 DOI: 10.1111/j.1460-9568.2004.03834.x  0.56
2005 Dass B, Iravani MM, Huang C, Barsoum J, Engber TM, Galdes A, Jenner P. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat Journal of Neural Transmission. 112: 763-778. PMID 15586304 DOI: 10.1007/s00702-004-0227-7  0.56
2005 Lane EL, Cheetham S, Jenner P. Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. The Journal of Pharmacology and Experimental Therapeutics. 312: 1124-31. PMID 15542624 DOI: 10.1124/jpet.104.076554  0.56
2005 Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 306-14. PMID 15490461 DOI: 10.1002/mds.20317  0.56
2005 Jenner P. Novel therapeutic approaches to the treatment of parkinson's disease Principles of Treatment in Parkinson's Disease. 333-359. DOI: 10.1016/B978-0-7506-5428-9.50019-6  0.44
2004 Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacology, Biochemistry, and Behavior. 79: 391-400. PMID 15582011 DOI: 10.1016/j.pbb.2004.07.015  0.56
2004 Gu M, Iravani MM, Irvani M, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry. 91: 1075-81. PMID 15569251 DOI: 10.1111/j.1471-4159.2004.02804.x  0.44
2004 Iczkiewicz J, Rose S, Jenner P. Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Research. Molecular Brain Research. 132: 64-72. PMID 15548430 DOI: 10.1016/j.molbrainres.2004.09.013  0.56
2004 Iravani MM, Liu L, Rose S, Jenner P. Role of inducible nitric oxide synthase in N-methyl-d-aspartic acid-induced strio-nigral degeneration. Brain Research. 1029: 103-13. PMID 15533321 DOI: 10.1016/j.brainres.2004.09.033  0.56
2004 Zeng BY, Heales SJR, Canevari L, Rose S, Jenner P. Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice Experimental Neurology. 190: 515-524. PMID 15530890 DOI: 10.1016/j.expneurol.2004.08.022  0.56
2004 Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology. 63: S13-22. PMID 15477581  0.56
2004 Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 997-1005. PMID 15372588 DOI: 10.1002/mds.20243  0.44
2004 Hyun DH, Gray DA, Halliwell B, Jenner P. Interference with ubiquitination causes oxidative damage and increased protein nitration: implications for neurodegenerative diseases. Journal of Neurochemistry. 90: 422-30. PMID 15228598 DOI: 10.1111/j.1471-4159.2004.02493.x  0.56
2004 Whitehead KJ, Rose S, Jenner P. Halothane Anesthesia Affects NMDA-Stimulated Cholinergic and GABAergic Modulation of Striatal Dopamine Efflux and Metabolism in the Rat In Vivo Neurochemical Research. 29: 835-842. PMID 15098949 DOI: 10.1023/B:NERE.0000018858.64265.e9  0.44
2004 Löschmann PA, De Groote C, Smith L, Wüllner U, Fischer G, Kemp JA, Jenner P, Klockgether T. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Experimental Neurology. 187: 86-93. PMID 15081591 DOI: 10.1016/j.expneurol.2004.01.018  0.44
2004 Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. The Journal of Pharmacology and Experimental Therapeutics. 309: 921-35. PMID 14978195 DOI: 10.1124/jpet.103.062414  0.44
2004 Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates Movement Disorders. 19: 15-21. PMID 14743355 DOI: 10.1002/mds.10596  0.56
2004 Jenner P, Obeso, Olanow, Brooks, LeWitt, Stocchi, Hauser. Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation Neurology. 62: S47-S55. PMID 14718680  0.44
2004 Zeng BY, Smith LA, Pearce RKB, Tel B, Chancharme L, Moachon G, Jenner P. Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets Neuroscience Letters. 354: 6-9. PMID 14698469 DOI: 10.1016/j.neulet.2003.08.038  0.56
2004 Kase H, Mori A, Jenner P. Adenosine A2A-receptor antagonists: Beyond dopaminergic therapies for Parkinson's disease Drug Discovery Today: Therapeutic Strategies. 1: 51-57. DOI: 10.1016/j.ddstr.2004.08.016  0.56
2003 Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Current Opinion in Neurology. 16: S3-7. PMID 15180131  0.56
2003 Jenner P. A2A antagonists as novel nondopaminergic therapy for motor dysfunction in PD Neurology. 61: S32-S38. PMID 14663007  0.56
2003 Hurley MJ, Mash DC, Jenner P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain Journal of Neural Transmission. 110: 1279-1288. PMID 14628192 DOI: 10.1007/s00702-003-0033-7  0.44
2003 Hurley MJ, Mash DC, Jenner P. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. The European Journal of Neuroscience. 18: 2668-72. PMID 14622169 DOI: 10.1046/j.1460-9568.2003.02963.x  0.44
2003 Iravani MM, Jackson MJ, Kuoppamäki M, Smith LA, Jenner P. 3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates Journal of Neuroscience. 23: 9107-9115. PMID 14534244  0.56
2003 Gilbert EA, Edwards RJ, Boobis AR, Rose S, Jenner P. Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon. Journal of Neural Transmission (Vienna, Austria : 1996). 110: 1091-101. PMID 14523622 DOI: 10.1007/s00702-003-0029-3  0.56
2003 Jenner P. The MPTP-treated primate as a model of motor complications in PD: Primate model of motor complications Neurology. 61: S4-S11. PMID 14504374  0.44
2003 Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD. Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism Pharmacology Biochemistry and Behavior. 75: 627-633. PMID 12895680 DOI: 10.1016/S0091-3057(03)00129-1  0.44
2003 Hyun DH, Lee M, Halliwell B, Jenner P. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins Journal of Neurochemistry. 86: 363-373. PMID 12871577 DOI: 10.1046/j.1471-4159.2003.01841.x  0.44
2003 Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure Movement Disorders. 18: 487-495. PMID 12722161 DOI: 10.1002/mds.10394  0.56
2003 Jenner P, Hunot, Olanow, Beal, Kordower, Tatton, Schapira. Oxidative stress in Parkinson's disease Annals of Neurology. 53: S26-S38. PMID 12666096 DOI: 10.1002/ana.10483  0.56
2003 Kunikowska G, Jenner P. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease Brain Research. 968: 206-218. PMID 12663090 DOI: 10.1016/S0006-8993(03)02240-6  0.56
2003 Treseder SA, Rose S, Summo L, Jenner P. Commonly used L-amino acid decarboxylase inhibitors block monoamine oxidase activity in the rat Journal of Neural Transmission. 110: 229-238. PMID 12658372 DOI: 10.1007/s00702-002-0778-4  0.56
2003 Silva MT, Rose S, Hindmarsh JG, Jenner P. Inhibition of neuronal nitric oxide synthase increases dopamine efflux from rat striatum Journal of Neural Transmission. 110: 353-362. PMID 12658363 DOI: 10.1007/s00702-002-0791-7  0.56
2003 Cannizzaro C, Tel BC, Rose S, Zeng BY, Jenner P. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease Molecular Brain Research. 110: 169-176. PMID 12591154 DOI: 10.1016/S0169-328X(02)00555-7  0.56
2003 Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease Parkinsonism and Related Disorders. 9: 131-137. PMID 12573867 DOI: 10.1016/S1353-8020(02)00115-3  0.56
2003 Maratos EC, Jackson MJ, Pearce RKB, Cannizzaro C, Jenner P. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus) Experimental Neurology. 179: 90-102. PMID 12504871 DOI: 10.1006/exnr.2002.8055  0.44
2003 McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Experimental Neurology. 179: 38-46. PMID 12504866 DOI: 10.1006/exnr.2002.8050  0.56
2003 Jenner P. Introduction: Agonizing over agonists Current Opinion in Neurology. 16: S1. DOI: 10.1097/00019052-200312001-00001  0.56
2002 Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P, Rice-Evans CA. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion Free Radical Biology and Medicine. 33: 1693-1702. PMID 12488137 DOI: 10.1016/S0891-5849(02)01137-1  0.56
2002 McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. The European Journal of Neuroscience. 16: 2136-48. PMID 12473081 DOI: 10.1046/j.1460-9568.2002.02301.x  0.56
2002 Kuoppamäki M, Al-Barghouthy G, Jackson M, Smith L, Zeng BY, Quinn N, Jenner P. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levopoda Movement Disorders. 17: 1312-1317. PMID 12465074 DOI: 10.1002/mds.10263  0.56
2002 Tel BC, Zeng BY, Cannizzaro C, Pearce RKB, Rose S, Jenner P. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets Neuroscience. 115: 1047-1058. PMID 12453478 DOI: 10.1016/S0306-4522(02)00535-3  0.56
2002 Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates Journal of Pharmacology and Experimental Therapeutics. 303: 952-958. PMID 12438514 DOI: 10.1124/jpet.102.039743  0.56
2002 Hyun DH, Lee MH, Halliwell B, Jenner P. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: A mechanism contributing to neurodegeneration? Journal of Neurochemistry. 83: 360-370. PMID 12423246 DOI: 10.1046/j.1471-4159.2002.01125.x  0.56
2002 Kunikowska G, Gallagher I, Glover V, Clow A, Jenner P. Effects of short- and long-term (-)-deprenyl administration on mRNA for copper, zinc- and manganese-superoxide dismutase and glutathione peroxidase in rat brain Brain Research. 953: 1-11. PMID 12384232 DOI: 10.1016/S0006-8993(02)03187-6  0.56
2002 Smith LA, Tel BC, Jackson MJ, Hansard M, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P. Repeated administration of piribedil induces less dyskinesia than L-Dopa in MPTP-treated common marmosets: A behavioral and biochemical investigation Movement Disorders. 17: 887-901. PMID 12360537 DOI: 10.1002/mds.10200  0.56
2002 Pearce RKB, Smith LA, Jackson MJ, Banerji T, Scheel-Krüger J, Jenner P. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets Movement Disorders. 17: 877-886. PMID 12360536 DOI: 10.1002/mds.10238  0.56
2002 Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates European Journal of Pharmacology. 451: 157-160. PMID 12231385 DOI: 10.1016/S0014-2999(02)02268-9  0.56
2002 Dass B, Iravani MM, Jackson MJ, Engber TM, Galdes A, Jenner P. Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets Neuroscience. 114: 99-109. PMID 12207958 DOI: 10.1016/S0306-4522(02)00214-2  0.44
2002 McNaught KS, Björklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport. 13: 1437-41. PMID 12167769  0.56
2002 McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neuroscience Letters. 326: 155-8. PMID 12095645 DOI: 10.1016/S0304-3940(02)00296-3  0.56
2002 Smith LA, Jackson MJ, Al-Barghouthy G, Jenner P. The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration Journal of Neural Transmission. 109: 123-140. PMID 12075853 DOI: 10.1007/s007020200009  0.44
2002 Spencer JP, Whiteman M, Jenner P, Halliwell B. 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. Journal of Neurochemistry. 81: 122-9. PMID 12067224 DOI: 10.1046/j.1471-4159.2002.00808.x  0.44
2002 McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. Journal of Neurochemistry. 81: 301-6. PMID 12064477 DOI: 10.1046/j.1471-4159.2002.00821.x  0.56
2002 Hyun DH, Lee M, Hattori N, Kubo SI, Mizuno Y, Halliwell B, Jenner P. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome Journal of Biological Chemistry. 277: 28572-28577. PMID 12034719 DOI: 10.1074/jbc.M200666200  0.56
2002 Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, Jenner P. 6-Hydroxydopamine lesioning differentially affects α-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats Neuroscience Letters. 322: 33-36. PMID 11958837 DOI: 10.1016/S0304-3940(02)00083-6  0.56
2002 Kunikowska G, Jenner P. The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia Biochemical Pharmacology. 63: 1159-1164. PMID 11931849 DOI: 10.1016/S0006-2952(01)00897-8  0.56
2002 Perry NS, Houghton PJ, Jenner P, Keith A, Perry EK. Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 9: 48-51. PMID 11926204 DOI: 10.1078/0944-7113-00082  0.56
2002 Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease Neurology. 58: S1-S8. PMID 11909980  0.44
2002 Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration Neuroscience. 110: 49-58. PMID 11882372 DOI: 10.1016/S0306-4522(01)00562-0  0.56
2002 Lyras L, Zeng BY, McKenzie G, Pearce RKB, Halliwell B, Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys Journal of Neural Transmission. 109: 53-67. PMID 11793162 DOI: 10.1007/s702-002-8236-2  0.44
2002 Whitehead KJ, Rose S, Jenner P. Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats European Journal of Neuroscience. 14: 851-860. DOI: 10.1046/j.0953-816x.2001.01702.x  0.44
2001 Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernández-Ruiz JJ. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. The European Journal of Neuroscience. 14: 1827-32. PMID 11860478 DOI: 10.1046/j.0953-816X.2001.01812.x  0.56
2001 Lee M, Hyun DH, Marshall KA, Ellerby LM, Bredesen DE, Jenner P, Halliwell B. Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. Free Radical Biology & Medicine. 31: 1550-9. PMID 11744329 DOI: 10.1016/S0891-5849(01)00633-5  0.56
2001 Kunikowska G, Jenner P. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase Brain Research. 922: 51-64. PMID 11730701 DOI: 10.1016/S0006-8993(01)03149-3  0.56
2001 Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study. Journal of Neural Transmission (Vienna, Austria : 1996). 108: 925-41. PMID 11716146 DOI: 10.1007/s007020170013  0.44
2001 Medhurst AD, Zeng BY, Charles KJ, Gray J, Reavill C, Hunter AJ, Shale JA, Jenner P. Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment. Neuroscience. 105: 353-64. PMID 11672603 DOI: 10.1016/S0306-4522(01)00190-7  0.44
2001 Ferger B, Themann C, Rose S, Halliwell B, Jenner P. 6-Hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: Implication of peroxynitrite formation Journal of Neurochemistry. 78: 509-514. PMID 11483653 DOI: 10.1046/j.1471-4159.2001.00429.x  0.44
2001 Ferger B, Rose S, Jenner A, Halliwell B, Jenner P. 6-Hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum Neuroreport. 12: 1155-1159. PMID 11338183  0.44
2001 Hurley MJ, Mash DC, Jenner P. Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson's disease Molecular Brain Research. 87: 271-279. PMID 11245931 DOI: 10.1016/S0169-328X(01)00022-5  0.44
2001 Iravani MM, Costa S, Jackson MJ, Tel BC, Cannizzaro C, Pearce RKB, Jenner P. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets European Journal of Neuroscience. 13: 597-608. PMID 11168568 DOI: 10.1046/j.1460-9568.2001.01408.x  0.44
2001 Treseder SA, Rose S, Jenner P. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats European Journal of Neuroscience. 13: 162-170. PMID 11135014 DOI: 10.1046/j.0953-816X.2000.01370.x  0.44
2000 Treseder SA, Smith LA, Jenner P. Voxel-based distribution of metabolic impairment in corticobasal degeneration Movement Disorders. 15: 894-904. PMID 11009197 DOI: 10.1002/1531-8257(200009)15:5<894::AID-MDS1021>3.0.CO;2-S  0.44
2000 Hurley MJ, Mash DC, Jenner P. Adenosine A(2A) receptor mRNA expression in Parkinson's disease Neuroscience Letters. 291: 54-58. PMID 10962152 DOI: 10.1016/S0304-3940(00)01371-9  0.44
2000 Smith LA, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RKB, Jenner P. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset Clinical Neuropharmacology. 23: 133-142. PMID 10895396 DOI: 10.1097/00002826-200005000-00002  0.44
2000 Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP- treated primates Annals of Neurology. 47: S90-S104. PMID 10762136  0.44
2000 Treseder SA, Jackson M, Jenner P. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates British Journal of Pharmacology. 129: 1355-1364. PMID 10742291  0.44
2000 Kanda T, Jackson MJ, Smith LA, Pearce RKB, Nakamura J, Kase H, Kuwana Y, Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Experimental Neurology. 162: 321-327. PMID 10739638 DOI: 10.1006/exnr.2000.7350  0.44
2000 Olanow CW, De Vivo DC, Obeso J, Johnston MV, Jenner P. Annals of Neurology: Foreword Annals of Neurology. 47: S1.  0.44
1999 Pearce RKB, Costa S, Jenner P, Marsden CD. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets Journal of Neural Transmission. 106: 663-683. PMID 10907726 DOI: 10.1007/s007020050188  0.44
1999 Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, Poewe W, Wenning GK. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts Neuroscience. 95: 377-388. PMID 10658617 DOI: 10.1016/S0306-4522(99)00457-1  0.44
1999 McNaught KSP, Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures Journal of Neurochemistry. 73: 2469-2476. PMID 10582607 DOI: 10.1046/j.1471-4159.1999.0732469.x  0.44
1999 Marshall KA, Reist M, Jenner P, Halliwell B. The neuronal toxicity of sulfite plus peroxynitrite is enhanced by glutathione depletion: implications for Parkinson's disease. Free Radical Biology & Medicine. 27: 515-20. PMID 10490270 DOI: 10.1016/S0891-5849(99)00094-5  0.44
1999 Rose S, Hindmarsh JG, Jenner P. Neuronal nitric oxide synthase inhibition reduces MPP +-evoked hydroxyl radical formation but not dopamine efflux in rat striatum Journal of Neural Transmission. 106: 477-486. PMID 10443551 DOI: 10.1007/s007020050172  0.44
1999 Riedl AG, Watts PM, Brown CT, Jenner P. P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson's disease Advances in Neurology. 80: 271-286. PMID 10410732  0.44
1999 Rose S, MacKenzie GM, Jenner P. Nitric oxide and basal ganglia degeneration. Advances in Neurology. 80: 247-57. PMID 10410729  0.44
1999 Dexter DT, Ward RJ, Florence A, Jenner P, Crichton RR. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat. Biochemical Pharmacology. 58: 151-5. PMID 10403528 DOI: 10.1016/S0006-2952(99)00079-9  0.44
1999 Pearce RKB, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets Psychopharmacology. 142: 51-60. PMID 10102782 DOI: 10.1007/s002130050861  0.44
1999 Love S, Jenner P. Oxidative stress in neurological disease Brain Pathology. 9: 55-56.  0.44
1998 Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. Journal of Neurochemistry. 71: 2431-8. PMID 9832141  0.44
1998 Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. Journal of Neurochemistry. 71: 2112-22. PMID 9798937  0.44
1998 McNaught KSP, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease Biochemical Pharmacology. 56: 921-933. PMID 9776302 DOI: 10.1016/S0006-2952(98)00142-7  0.44
1998 Kanda T, Tashiro T, Kuwana Y, Jenner P. Adenosine A(2A) receptors modify motor function in MPTP-treated common marmosets Neuroreport. 9: 2857-2860. PMID 9760134  0.44
1998 Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease Annals of Neurology. 44: S167-S174. PMID 9749590  0.44
1998 Jenner P, Olanow CW. Understanding cell death in Parkinson's disease Annals of Neurology. 44: S72-S84. PMID 9749577  0.44
Show low-probability matches.